Farther Finance Advisors’s Cartesian Therapeutics RNAC Stock Holding History

Farther Finance Advisors’s Portfolio RNAC Stock Details RNAC Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$1.39K	Buy	135 +78	+137%	+$578	﹤0.01%	5277
2026 Q1	$364	Buy	+57	New	+$406	﹤0.01%	5335
2025 Q2	–	Sell	-539	Closed	–	–	4634
2025 Q1	$0	Buy	539 +521	+2,894%	+$9.31K	﹤0.01%	4398
2024 Q4	$322	Hold	18	–	–	﹤0.01%	3540
2024 Q3	$290	Hold	18	–	–	﹤0.01%	3565
2024 Q2	$436	Hold	18	–	–	﹤0.01%	3311
2024 Q1	$302	Sell	18 -18	-50%	-$382	﹤0.01%	3164
2023 Q4	$372	Buy	36 +18	+100%	+$537	﹤0.01%	3069
2023 Q3	$571	Hold	18	–	–	﹤0.01%	2231
2023 Q2	$604	Hold	18	–	–	﹤0.01%	2103
2023 Q1	$749	Hold	18	–	–	﹤0.01%	1909
2022 Q4	$609	Buy	+18	New	+$766	﹤0.01%	1793

Other funds holding RNAC

IFP Advisors Tampa, Florida $5.54B AUM 27.43% 1-Year Est. Return

GAMMA Investing Foster City, California $2.69B AUM 42.78% 1-Year Est. Return

TWD

True Wealth Design Akron, Ohio $420M AUM 22.7% 1-Year Est. Return

AWM

Activest Wealth Management Aventure, Florida $518M AUM 44.34% 1-Year Est. Return

Farther Finance Advisors's RNAC Position: Q2 2026 in Review

Farther Finance Advisors increased its Cartesian Therapeutics (RNAC) stake by 137% in Q2 2026, buying an estimated $578 and bringing the position to 135 shares worth $1.39K. The position accounts for ﹤0.01% of the portfolio, ranked #5277.

Farther Finance Advisors first reported a position in RNAC in Q4 2022 and has held it in 12 quarters since. 5 funds tracked by Wall St. Rank hold RNAC as of Q2 2026.

Farther Finance Advisors held 135 shares of Cartesian Therapeutics worth $1.39K as of Q2 2026.
Farther Finance Advisors bought 78 Cartesian Therapeutics shares in Q2 2026, an estimated $578.
Cartesian Therapeutics made up ﹤0.01% of Farther Finance Advisors's portfolio in Q2 2026, its #5277 holding.
Farther Finance Advisors first reported a position in Cartesian Therapeutics in Q4 2022 and has held it in 12 quarters since.
5 funds tracked by Wall St. Rank held Cartesian Therapeutics as of Q2 2026.

Based on Farther Finance Advisors's 13F filing for Q2 2026, filed 17 Jul 2026.